Amphotericin B Lipid Complex in the Management of Antimony Unresponsive Indian Visceral Leishmaniasis

Journal of Association of Physicians of India

Volumn 47, Issue 3, 1999, Pages 186-188

  Sundar, S ^a   Goyal, A K ^a   Mandal, A K ^a   Makharia, M K ^a   Singh, V P ^a   Murray, H W ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIMONY; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG RESISTANCE; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ANTIMONY; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LEISHMANIASIS, VISCERAL; MALE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; PROBABILITY; TREATMENT OUTCOME;

EID: 0033068759     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Sundar S, Rosenkaimer F, Murray HW. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-γ. J Infect Dis 1994; 170 : 659-62.
2. Sunder S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon- τ plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis 1997; 174 : 1117-9.
3. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994; 344 : 1599-600.
4. World Health Organisation. The control of Leishmaniasis: report of an expert committee. WHO Tech Rep Ser 1990; 793 : 50-5.
5. Sundar S. Treatment of visceral leishmaniasis - Current status. J Assoc Physicians India 1997; 45 : 640-5.
6. Jha TK. Evaluation of diamidine compounds (pentamidine isethionate) in the treatment of resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983; 77: 167-70.
7. Thakur CP, Kumar M, Pandey AK. Comparison of regimens of treatment of antimony-resistant kala-azar patients : a randomized study. Amer J Trop Med Hyg 1991; 45 : 435-41.
8. Dietze R, Milan EP, Berman JD, et al. Treatment of Brazilian Kala-azar with a short course Amphocil (Amphotericin B Cholesterol Dispersion). Clin Infect Dis 1993; 17 : 981-6.
9. Davidson RN, di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBiosome) in Mediterranean visceral leishmaniasis: a multi-centre trial. QJ Med 1994; 87 : 75-81.
10. Seaman J, Boer C, Wilkinson R, et al. Liposomal amphotericin B (Ambiosome) in the treatment of complicated kala-azar under filed conditions. Clin Infec Dis 1985; 21 : 18-193.
11. Sunder S, Murray HW. Cure of antimony-unresponsive Indian visceral leishmaniasis with liposomal amphotericin B lipid complex. J Infect Dis 1996; 173 : 762-5.
12. Sunder S, Agrawal NK, Sinha PR, Horwith G, Murray HW. Cure with short-course, low dose amphotericin B lipid complex therapy for antimony-unresponsive visceral leishmaniasis. Ann Int Med 1997; 127 : 133-137.